Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Takara Bio Inc. ( (JP:4974) ).
Takara Bio Inc. has announced its acquisition of Curio Bioscience, Inc. to enhance its capabilities in spatial analysis technology. This strategic move aims to leverage Curio’s advanced DNA-barcoded beads technology with Takara Bio’s existing genetic engineering expertise, fostering innovation and creating high-quality products and services for the growing NGS market. The acquisition is expected to strengthen Takara Bio’s position in the biotechnology sector, providing significant synergies and expanding their offerings in spatial analysis solutions.
More about Takara Bio Inc.
Takara Bio Inc. operates in the biotechnology industry, focusing on providing research reagents, scientific instruments, and contract services to researchers in both academia and industry. The company is particularly involved in the next-generation sequencing (NGS) market, offering products and services that align with emerging trends such as single cell analysis and spatial transcriptome analysis.
YTD Price Performance: -4.95%
Average Trading Volume: 206,491
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen120.2B
For an in-depth examination of 4974 stock, go to TipRanks’ Stock Analysis page.
